Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that effectively managing PCOS requires a multifaceted approach.

Proteins like aPKC and PDGF-AA, substances like adenosine and ATP, and adipose-derived stem cells all play important roles in hair growth and health, and could potentially be used to treat hair loss and skin conditions.

Metformin helps manage polycystic ovary syndrome by improving insulin resistance and ovulation, but more research is needed on its full effects.

Certain gene variants may contribute to high androgen levels in women with polycystic ovary syndrome.

Scalp hair grows at 0.37 mm/day, forearm hair at 0.18 mm/day, and thigh hair at 0.30 mm/day, with no significant differences found in people with certain hair conditions.

A cat with skin bumps and itching had high blood fats and skin infections, which improved with diet and medication changes.

Polycystic ovary syndrome is a common hormonal disorder in women, linked to increased risk of metabolic and heart diseases, and needs more research for better understanding and treatment.

Platelet-Rich Plasma (PRP), a protein-rich extract from a patient's blood, shows promise in improving hair density, thickness, and quality, but the best method of use and number of treatments needed for noticeable results are still unclear.

The study found that the hair loss condition in Cesky Fousek dogs is influenced by multiple genes affecting skin and muscle structure, fat metabolism, and immunity.

PCOS is a complex condition with major health impacts, needing more research for better diagnosis and treatment.

The document concludes that insulin resistance is key in PCOS development and early treatment is crucial to prevent complications.

The Rotterdam Study updated its design and objectives in 2012, providing insights into various diseases in the elderly, including skin cancer, bone health, liver disease, neurological and psychiatric conditions, and respiratory issues.

Polycystic Ovary Syndrome likely starts in childhood and may be genetic and influenced by early hormone exposure.

PCOS is a common hormonal disorder in women, marked by symptoms like hair growth and menstrual issues, and requires personalized treatment.

Male hormones are important for hair and oil gland development and can cause conditions like excessive hair growth and acne.

Dermatologists play a key role in treating skin symptoms of PCOS like dark patches, excess hair, acne, and hair loss.

Androstanediol glucuronide is a reliable marker for hirsutism in women.

Systemic Lupus Erythematosus has varied symptoms and is hard to diagnose, affecting many body parts and requiring careful clinical judgment.

Pregnancy can cause specific skin conditions that need correct diagnosis and treatment to protect both mother and baby.

New treatments for PCOS focus on insulin resistance and reducing testosterone levels, along with traditional hormone therapies.

Certain genetic variations are linked to increased androgen levels in PCOS, but more research is needed to understand these connections fully.

Finasteride reduces hirsutism effectively with fewer side effects but is a second-choice treatment due to safety concerns.

Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.

PCOS is a long-term condition that needs more research for better understanding and treatment.

Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.

The document concludes that managing PCOS involves lifestyle changes, medication for symptoms, and weight loss for fertility improvement.

Women with PCOS should have an oral glucose tolerance test for effective diabetes screening.

The document concludes that managing PCOS requires a comprehensive approach, including lifestyle changes and medication, to improve symptoms and reduce health risks.

Finasteride helps reduce hidradenitis suppurativa symptoms in females.

A woman lost over 80% of her hair due to a condition called telogen effluvium after having COVID-19.